The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Zsolt Megyesfalvi moderates a discussion in Hungarian about highlights from the conference with Dr. Zsuzsanna Keleman, Dr. Lilla Horvath, and Dr. Gyula Ostoros.

This episode of Lung Cancer Considered covers highlights from the 2025 ESMO Annual Meeting held October 17th to the 21st in Berlin, Germany. Guests are: Dr. Xiuning Le from MD Anderson Cancer Center in Houston, Texas. Dr. Pedro Rocha from Vall d’Hebron University Hospital in Barcelona, Spain. Dr. Riyaz Shah, a consultant medical oncologist at the Kent Oncology Centre in the United Kingdom.

In this episode of Lung Cancer Considered, Dr. Narjust Florez leads a discussion with Ann Fish-Steagall and Amanda Nerstad about the 2025 Lung Cancer Hope Summit. The team discusses highlights from the meeting, including groundbreaking research, innovative treatments, and patient advocacy.

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Helena Linardou moderates a discussion in Greek about highlights from the conference with Dr. Foteinos-Ioannis Dimitrakopoulos and Dr. Evangelos Sarris.

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of maintenance lurbinectedin plus atezolizumab for extensive stage small cell lung cancer, based on the phase III IMforte trial. Dr. Hossein Borghaei joins the podcast to explain the results and offer perspective on the impact of maintenance therapy for SCLC. Guest: Dr. Hossein Borghaei, DO, MS Chief, Division of Thoracic Medical Oncology Professor, Department of Hematology/Oncology Fox Chase Cancer Center

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Nagla Abdel Karim moderates a discussion in Arabic about highlights from the conference with Dr. Riad Abdeljalil, Dr. Khaled Abdel Aziz, Dr. Ashraf Abdel Ghani, Dr. Ahmed Rabea, and Dr. Hussein Soudy.

As part of IASLC’s ongoing series of Lung Cancer Considered podcasts in world languages, Dr. Lizza Hendriks moderates a discussion in Dutch with Dr. Marthe Paats and Dr. Gerrina Ruiter on the treatment of EGFR non-small cell lung cancer.

Lung Cancer Considered: Targeting EGFR NSCLC by IASLC

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Misako Nagasaka moderates a discussion in Japanese about highlights from the conference with Dr. Hidehito Horinouchi. Key Topics Covered: • WCLC 2025 highlights • FLAURA2 • HARMONi

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Chul Kim moderates a discussion in Korean about highlights from the conference with Dr. Jeongmin Seo and Dr. Min Hee Hong. Guest Host: Chul Kim, MD, MPH Thoracic Medical Oncologist and Associate Professor Georgetown University Instagram: @fe0120 Guest Name(s) & Title(s): Jeongmin Seo, MD, MSc Assistant Professor, Medical Oncology Seoul National University Bundang Hospital Min Hee Hong, MD Associate Professor, Yonsei Cancer Center Severance Hospital, Seoul

This episode of Lung Cancer Considered reviews new and upcoming approvals for subcutaneous immune checkpoint inhibitors. Join host Dr. Narjust Florez and guests, Dr. Cheryl Ho and Dr. Maria Velez Velez, for a discussion of the formulation and its place in the management of patients with lung cancer. Guests: Cheryl Ho, MD, FRCPC Thoracic Oncologist, BC Cancer Clinical Associate Professor and Fellowship Program Director University of British Columbia Maria Velez Velez, MD, MS Clinical Instructor, Division of Hematology/Oncology David Geffen School of Medicine at UCLA

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, guest host Dr. Kuan Yu Chen moderates a discussion in Mandarin with Dr. Bin-Chi Liao and Dr. Jeng-Sen Tseng, leading lung cancer experts in Taiwan, who share their perspectives on key highlights from the conference.

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Clarissa Mathias moderates a discussion in Portuguese about highlights from the conference with Dr. Clarissa Baldotto, Dr. Lilian Faroni, Dr. Maria Cecilia Mathias, and Dr. William William, Jr.

In this episode, recorded live in Spanish at WCLC 2025, Dr. Diego Carrillo reflects on his experiences as a junior faculty member at WCLC 2025. In conversation with host Dr. Narjust Florez, they discuss conference activities, research highlights, and how WCLC helps junior faculty build their networks and shape the future of lung cancer care and research.

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Alona Zer moderates a discussion in Hebrew about highlights from the conference with Dr. Haitam Nasrallah, Dr. Jair Bar, and Dr. Ory Wiesel.

In this special WCLC 2025 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss highlights from the conference. Dr. Susan Scott discusses EGFR mutant NSCLC and results from PALOMA-2 and subcutaneous amivantamab. Dr. Wenfeng Fang discusses Iza-Bren (BL-D01D1), a first-in-class EGFR x HER-3 biospecific ADC linked to a novel topoisomerase I inhibitor payload, with promising preliminary activity in EGFR positive previously treated NSCLC. Dr. Biagio Ricciuti shares his insights from WCLC 2025, including the FLAURA-2 OS readout, the HARMONi trial in EGFR positive NSCLC, and his research in the use of immunotherapy in early-stage lung cancer.

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Narjust Florez moderates a discussion in Spanish about highlights from the conference with Dr. Laura Mezquita and Dr. Jorge Alatorre Alexander.

In this special WCLC 2025 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss daily highlights from the conference. Dr. Tina Cascone discusses results from the NADIM ADJUVANT Phase III trial. Dr. Jacie Jiaqi Law shares survival outcomes of VATS compared to open lobectomy, and Dr. Corinne Faivre-Finn and Dr. Shankar Siva summarize results from the EA5181 trial of concurrent and consolidation durvalumab after chemoradiation for unresectable NSCLC and hypofractionation vs conventional fractionation for LS SCLC.

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Chunxia Su moderates a discussion in Mandarin Chinese about highlights from the conference with Dr. Yang Xia and Dr. Nan Bi.

In this special WCLC 2025 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss daily highlights from the conference. Dr. David Planchard discusses the data that we all were waiting for the FLAURA-2 overall survival. Dr. Alexander Drilon shares results from the ARROS-1 study including efficacy results and safety data for zidesamtinib, a new ROS1 inhibitor that could change the landscape in the ROS1 space.